Carbon Silicon Ventures

Leading DNA Synthesis Company that manufactures synthetic DNA, overcoming limitations of traditional methods to empower scientists in health and sustainability.

Octant is a therapeutics company building small molecule drugs that modulate cellular mechanisms. They focus on next-generation drug discovery using synthetic biology, high throughput chemistry, and AI/ML to target complex diseases, particularly those caused by protein misfolding.

Basepair offers a next-generation sequencing (NGS) data analysis platform that specializes in genomics, transcriptomics, and epigenetics, providing solutions for biopharma, diagnostics, and academic research.

Sphinx Bio is a cloud-based data management and analysis platform designed for the life sciences, aimed at accelerating drug discovery through modern biotech data solutions.

Current Surgical is reinventing surgery through a digital platform that integrates AI-driven algorithms and focused ultrasound technology to enhance precision in surgical procedures, aiming to improve outcomes and reduce risks in treating various conditions, including cancer.

Medra is an innovative company that integrates Physical AI and Scientific AI to automate laboratory protocols and enhance data generation in life sciences. Their autonomous robotic systems are designed to execute scientific protocols with precision and efficiency, enabling breakthroughs in research and experimentation.

Olden Labs is dedicated to improving animal research through innovative technologies such as AI and robotics, aiming to enhance the quality and efficiency of animal studies while ensuring animal welfare.

Bluenote Health is an AI platform designed to streamline regulatory and compliance workflows in the life sciences sector, enabling faster submission of drug and device approvals.

Founded by Bryan Johnson, invests in platforms and enabling technologies supporting inventors and scientists building programmable-biology solutions to rewrite life's operating systems and benefit humanity. OS Fund believes biology is programmable, and invests in platforms and enabling technologies (i.e. Ginkgo Bioworks).

Bioscience investor translating grant-funded research into venture-scale companies, with a pipeline centered on engineering biology using robotic cloud labs and computational design for human health and planetary sustainability. The firm grew directly out of a philanthropic grants program at the Thiel Foundation that funded highly speculative science before spinning into a traditional venture fund.

Flagship Pioneering operates as an "institutional innovation" model that internally originates 80-100 "explorations" per year through Flagship Labs based on "What if…?" hypotheses, then systematically evolves promising ideas through a staged company-creation funnel (Explorations → ProtoCos → NewCos → GrowthCos) that it fully founds, funds, and owns through early stages. The firm positions itself as principal founder rather than a traditional investor, building "bioplatform" companies organized around proprietary discovery engines and operating its own drug development unit, Pioneering Medicines, which partners directly with large pharmas like Pfizer and Novo Nordisk to co-create therapeutics.

Writes first institutional checks ($500k–$5M) at earliest stages for compute-applied chemistry and biology ventures (therapeutics, industrial biotech, climate, materials), led by an advanced-degree scientific team.

Early-stage accelerator for synthetic biology and life sciences that gives scientist-founders lab independence with co-located BSL-rated wet labs and extended runway via SOSV integration reserving 75% for follow-ons. The world's first startup accelerator focused specifically on synthetic biology and life sciences, created to give scientists independence as founders rather than forcing them into traditional academic or big-pharma tracks. The program runs its own large wet-lab infrastructure where portfolio companies co-locate and build in BSL-rated labs owned by the fund, while providing an unusually long runway of capital through deep integration with SOSV's fund structure that reserves 75% for follow-on rounds.